Arcus Biosciences, Inc. (RCUS)
NYQ – Real Time Price. Currency in USD
28.83
+0.09 (0.30%)
Market open: Aug 12, 2026, 3:36 PM EDT
28.74
0.00 (0.00%)
Previous after-hours: Aug 11, 2026, 7:34 PM EDT
Find any stock by ticker or company name

NYQ – Real Time Price. Currency in USD
28.83
+0.09 (0.30%)
Market open: Aug 12, 2026, 3:36 PM EDT
28.74
0.00 (0.00%)
Previous after-hours: Aug 11, 2026, 7:34 PM EDT
No Data
There are no news for this stock.
Company's cash reserves $150.0M significantly exceed its total debt $114.0M, ensuring strong financial flexibility
Total current assets $756.0M exceed Total current liabilities $198.0M, highlighting excellent liquidity
Debt-to-equity ratio (0.2) is well below the industry average (0.3), showcasing prudent financial management
Interest coverage ratio (-32.0x) is dangerously low, suggesting debt repayment risks
Negative free cash flow -$119.0M limits the company's ability to reinvest or pay down debt
| NAME | RATIO | INDUSTRY | 5Y TREND | SCORE |
|---|---|---|---|---|
| Current ratio | 3.82 | 6.05 | 10 | |
| Quick ratio | 3.82 | 5.63 | 10 | |
| Debt to Equity | 0.25 | 0.30 | 8.0 | |
| Debt to Assets | 0.12 | 1.04 | 8.0 | |
| Interest coverage | -32.00 | -16.91 | 1.0 | |
| Weighted average score | 7.4 | |||
| METRIC | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Total Revenue | 112M | 117M | 258M | 247M | 117M |
| Gross Profit | 98M | 101M | 248M | 237M | 108M |
| Operating Income | -280M | -340M | -310M | -386M | -486M |
| Net Income | -267M | -307M | -283M | -353M | -460M |
| EBITDA | -266M | -324M | -300M | -376M | -477M |
| NAME | REVENUE GROWTH | EPS GROWTH | SCORE |
|---|---|---|---|
| Current quarter | -47.23 | 27.26 | 5.5 |
| Next quarter | -64.13 | -2.18 | 1.0 |
| Current year | -69.3 | -11.74 | 1.0 |
| Next year | -14.9 | 4.76 | 2.5 |
| Weighted average score | 2.5 | ||
| NAME | REVENUE | NET INCOME | EPS | FCF | SCORE |
|---|---|---|---|---|---|
| Q/Q | 141.18 | 28.91 | 29.41 | 13.77 | 9.5 |
| Y/Y | -74.37 | 999 | 999 | 10.53 | 7.0 |
| 3y average | 40.24 | -10.61 | 2.57 | -101.56 | 4.0 |
| 5y average | 88.78 | -98.84 | -96.61 | -82.53 | 3.3 |
| Weighted average score | 6.0 | ||||
Insufficient positive free cash flow for DCF analysis
| NAME | CURRENT | INDUSTRY | SCORE |
|---|---|---|---|
| Dividend yield | 0.00 | N/A | 1.0 |
| Payout ratio | 0.00 | N/A | 1.0 |
| 5-year dividend growth rate | N/A | N/A | 1.0 |
| Years of dividend increase | N/A | N/A | 1.0 |
| Weighted average score | 1.0 | ||
Insufficient positive free cash flow for DCF analysis
| NAME | SCALE | SCORE |
|---|---|---|
| Market share | None | 1.0 |
| Intangible assets | None | 1.0 |
| Switching costs | None | 1.0 |
| Network effect | None | 1.0 |
| Economies of scale | None | 1.0 |
| Weighted average score | 1.0 | |